Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Na ïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Hormones | Pharmaceuticals | Prostate Cancer | Radiography